You are viewing an expired study

This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please browse nearby listings below.

Click here to view additional nearby studies or search for clinical trials.

Nashville, Tennessee 37232

  • Diabetic Ketoacidosis

Purpose:

The purpose of this study is to determine the effects of the addition of insulin glargine during the early phase of moderate to severe Diabetic Ketoacidosis (DKA) in children. The investigators hypothesize that the addition of insulin glargine during the early phase of management of DKA will accelerate acidosis correction, decrease the length of insulin infusion, and decrease the total intensive care unit time in children admitted to the ICU.


Criteria:

Inclusion Criteria: - Ages 6-18 y.o. presenting to Vanderbilt Children's Hospital (VCH) Emergency Room with: - Established history of insulin dependent diabetes AND: - Chief c/o hyperglycemia or vomiting - Venous pH < 7.24 - Serum Bicarbonate < 18 - Blood glucose > 150 - Urinary Ketones Exclusion Criteria: - Age < 6y.o. - New onset diabetes - Received IV insulin bolus prior to arrival to VCH Emergency Room (ER) - Venous pH > 7.24 - Serum Bicarbonate > 18 - Pregnancy - Received glargine within 12 hours prior to arrival to VCH Emergency Room/Pediatric Critical Care Unit


NCT ID:

NCT00179127


Primary Contact:

Principal Investigator
Sheila McMorrow, MD
Vanderbilt University


Backup Contact:

N/A


Location Contact:

Nashville, Tennessee 37232
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.